CoChat

HyperSightTM-CBCT based monitoring of sarcopenia during definitive radiotherapy of prostate cancer: a longitudinal feasibility study

Siefert, Victor, V. Bettenhausen, Joana, Bicu, Alicia S., Schmidt, Ralf, Willam, Marvin, Eckl, Miriam, Stieler, Florian, Ehmann, Michael, Buergy, Daniel, Fleckenstein, Jens, Beuthien-Baumann, Bettina, Schlemmer, Heinz-Peter, Froelich, Matthias F., Schoenberg, Stefan O., Giordano, Frank A., Boda-Heggemann, Judit, Dreher, Constantin · 2026 · Radiation Oncology
Cited by 0

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: Sarcopenia and treatment-related muscle loss are associated with increased toxicity and reduced resilience in cancer patients. HyperSight™ cone-beam CT (CBCT) provides improved soft-tissue contrast compared with conventional CBCT and may enable reliable longitudinal skeletal-muscle monitoring during image-guided radiotherapy (IGRT). This study evaluated the feasibility of HyperSight™ CBCT-based muscle assessment in prostate cancer patients and explored the clinical relevance of intratreatment muscle decline. Methods: Eighty-eight patients with non-metastatic prostate cancer were treated on an Ethos ® system with HyperSight™ CBCT. Patients received ultrahypofractionated (UHF) or normo-/moderately hypofractionated (NF/MHF) radiotherapy; 28% received androgen-deprivation therapy. Cross-sectional muscle area (CSA) and radiodensity (HU) were assessed on planning CT (PCT) and serial CBCTs (first, second, last fraction [FF, SF, LF]); HU values were z-standardized to subcutaneous fat (zHU). Agreement between PCT and CBCT was evaluated using concordance correlation coefficients (CCC), regression, and Bland-Altman analysis. Longitudinal changes were analyzed using mixed-effects models, and associations with acute genitourinary/gastrointestinal (GU/GI) toxicity (RTOG ≥ 2) using regression models. Results: HyperSight™ CBCT showed excellent agreement with PCT for CSA (CCC = 0.981). The NF/MHF cohort showed a significant longitudinal CSA decline (FF-LF: -153.0 mm², p = 0.021), whereas no significant within-cohort change was observed in UHF. Muscle density (zHU) decreased significantly in both cohorts (NF/MHF: p < 0.001; UHF: p = 0.0017). Weight loss and age were independently associated with zHU change, while no independent predictors of CSA decline were identified. In the NF/MHF cohort, CSA loss > 5% was associated with acute GU toxicity in univariate analysis (OR 4.90, p = 0.033; Fisher’s exact p = 0.014), but not after adjustment for age, weight loss, ECOG performance status, and ADT; no associations were found for GI toxicity or in the UHF cohort. Conclusions: HyperSight™ CBCT enables quantitative skeletal-muscle assessment during prostate radiotherapy and detects intratreatment reductions in muscle density, which may represent an early imaging marker of muscle decline. Muscle loss showed an exploratory association with acute GU toxicity in NF/MHF patients in univariate analysis, but not after adjustment. These findings support the feasibility of CBCT-based muscle monitoring and warrant further evaluation in larger cohorts. Clinical trial number: Not applicable.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13014-026-02856-3

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 41

  1. Baracos VE. Cancer-associated malnutrition. Eur J Clin Nutr. 2018;72(9):1255–9. · DOI · Paper page
  2. Duan K, Gao X, Zhu D. The clinical relevance and mechanism of skeletal muscle wasting. Clin Nutr. 2021;40(1):27–37. · DOI
  3. Vickers AJ, McSweeney DM, Choudhury A, Weaver J, Price G, McWilliam A. The prognostic significance of sarcopenia in patients treated with definitive radiotherapy: A systematic review. Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol. 2025;203:110663. · DOI · Paper page
  4. Perrier M, Fontaine M, Bertin E, Carlier C, Botsen D, Djelouah M, et al. Impact of low muscle mass and myosteatosis on treatment toxicity and survival outcomes in non-resectable pancreatic cancer patients treated with chemoradiotherapy. Eur J Clin Nutr. 2025;79(6):576–586. · DOI
  5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23. · DOI · Paper page
  6. Beaudart C, McCloskey E, Bruyère O, Cesari M, Rolland Y, Rizzoli R, et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16(1):170. · DOI · Paper page
  7. Sousa IM, Silva FM, das Virgens IPA, Costa EC, Fayh APT. Independent and joint association of sarcopenia and frailty with mortality in older patients with gastrointestinal cancer: a cohort study with prospective data collection. Support Care Cancer. 2023;31(12):728.
  8. da Silva Nascimento ML, Alves Bennemann N, de Sousa IM, de Oliveira Bezerra MR, Villaça Chaves G, Moreira Lima Verde SM, et al. Examining variations in body composition among patients with colorectal cancer according to site and disease stage. Sci Rep. 2024;14(1):10829. · DOI
  9. Vickers A, Choudhury A, McWilliam A, McSweeney DM, Price G, Weaver J. Sarcopenia does not predict increased acute or late radiotherapy related toxicities in prostate cancer patients. Clin Oncol. 2025;38. · DOI
  10. Fecteau R, Lee WR. The importance of body composition in patients with prostate cancer receiving radiotherapy. Cancer (0008543X). 2023;129(5). · doi:10.1002/cncr.34594
  11. Lee J, Park JS, Heo JE, Ahn HK, Jang WS, Ham WS, et al. Muscle characteristics obtained using computed tomography as prognosticators in patients with castration-resistant prostate cancer. Cancers (Basel). 2020;12(7). · DOI
  12. McDonald AM, Swain TA, Mayhew DL, Cardan RA, Baker CB, Harris DM, et al. CT Measures of Bone Mineral Density and Muscle Mass Can Be Used to Predict Noncancer Death in Men with Prostate Cancer. Radiology. 2017;282(2):475–83. · DOI
  13. Chiang PK, Tsai WK, Chiu AW, Lin JB, Yang FY, Lee J. Muscle Loss During Androgen Deprivation Therapy Is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer. Front Oncol. 2021;11:722652. · DOI · Paper page
  14. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271–6. · DOI · Paper page
  15. Huang W, Tan P, Zhang H, Li Z, Lin H, Wu Y, et al. Skeletal Muscle Mass Measurement Using Cone-Beam Computed Tomography in Patients With Head and Neck Cancer. Front Oncol. 2022;12:902966. · DOI
  16. Gallo P, D’Alessio A, Pascuzzo R, Gallo S, Fumagalli ML, Ortenzia O, et al. Enhancing Soft Tissue Differentiation with Different Dual-Energy CT Systems: A Phantom Study. Appl Sci. 2024;14(5):1724. · DOI
  17. Zannoni S, Albano D, Jannone ML, Messina C, Sconfienza LM. Correlation between muscle mass and quality around the hip and of psoas muscles at L3 level using unenhanced CT scans. Skeletal Radiol. 2020;49(10):1649–55. · DOI
  18. Lustermans D, Fonseca GP, Taasti VT, van de Schoot A, Petit S, van Elmpt W, et al. Image quality evaluation of a new high-performance ring-gantry cone-beam computed tomography imager. Phys Med Biol. 2024;69(10):105018. · DOI
  19. Schmidt R, Nguyen T, Bicu AS, Cvachovec P, Siefert V, Eckl M, et al. Advanced HyperSight™ imaging for patients with adaptive SBRT of prostate cancer: a longitudinal analysis of tissue demarcation. Radiat Oncol. 2025;20(1):153. · doi:10.1186/s13014-025-02730-8
  20. Siefert V, Haag F, Bicu AS, Schmidt R, Willam M, Eckl M, et al. Advanced Reliability of Radiomic Features in Ex Vivo Hypersight(TM)-CBCT Imaging by iCBCT-Acuros Reconstruction. Anticancer Res. 2026;46(4):1785–98. · doi:10.21873/anticanres.18074
  21. Yashayaeva A, MacDonald RL, Zhan K, DeGiobbi J, McMaster N, McAloney D, et al. HyperSight CBCT image quality and metal artifact reduction for adaptive head and neck radiotherapy: Results from a prospective clinical trial. J Appl Clin Med Phys. 2025;26(12):e70338. · doi:10.1002/acm2.70338
  22. Nelson N, Oare C, Nelson G, Martin T, Huang Y-H, Zhao H. Feasibility of HyperSight CBCT for adaptive radiation therapy: a phantom benchmark study of dose calculation accuracy and delivery verification on the Halcyon. J Appl Clin Med Phys. 2025;26. · doi:10.1002/acm2.70245
  23. Wang A, Maslowski A, Messmer P, Lehmann M, Strzelecki A, Yu E, et al. Acuros CTS: A fast, linear Boltzmann transport equation solver for computed tomography scatter–Part II: System modeling, scatter correction, and optimization. Med Phys. 2018;45(5):1914–25. · doi:10.1002/mp.12849
  24. Washio H, Ohira S, Funama Y, Ueda Y, Morimoto M, Kanayama N, et al. Dose reduction and low-contrast detectability using iterative CBCT reconstruction algorithm for radiotherapy. Technol Cancer Res Treat. 2022;21:15330338211067312. · DOI
  25. Mao W, Liu C, Gardner SJ, Siddiqui F, Snyder KC, Kumarasiri A, et al. Evaluation and clinical application of a commercially available iterative reconstruction algorithm for CBCT-based IGRT. Technol Cancer Res Treat. 2019;18:1533033818823054. · DOI
  26. Derstine B, Holcombe S, Goulson R, Ross B, Wang N, Sullivan J, et al. Quantifying sarcopenia reference values using lumbar and thoracic muscle areas in a healthy population. J Nutr health aging. 2018;22(1):180–5. · DOI · Paper page
  27. Zhao X, Du Y, Yue H. Skeletal Muscle Segmentation at the Level of the Third Lumbar Vertebra (L3) in Low-Dose Computed Tomography: A Lightweight Algorithm. Tomography (Ann Arbor. Mich). 2024;10(9):1513–26.
  28. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006. · DOI · Paper page
  29. Khan B, Shukla PK, Ahirwar MK, Mishra M. Strategic analysis in prediction of liver disease using different classification algorithms. Handbook of Research on Disease Prediction Through Data Analytics and Machine Learning. IGI Global Scientific Publishing; 2021. pp. 437–49. · doi:10.4018/978-1-7998-2742-9.ch022
  30. Park SE, Hwang IG, Choi JH. Skeletal muscle loss and associated clinical outcomes in patients with small-cell lung cancer receiving concurrent chemoradiotherapy. BMC Cancer. 2025;25(1):1772. · DOI · Paper page
  31. Kiss N, Beraldo J, Everitt S. Early Skeletal Muscle Loss in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation and Relationship to Survival. Support Care Cancer. 2019;27(7):2657–64.
  32. Lopez P, Newton RU, Taaffe DR, Winters-Stone K, Galvão DA, Buffart LM. Moderators of resistance-based exercise programs’ effect on sarcopenia-related measures in men with prostate cancer previously or currently undergoing androgen deprivation therapy: An individual patient data meta-analysis. J Geriatr Oncol. 2023;14(5):101535. · DOI
  33. Varian. HyperSight: a revolution in resolution (HyperSight brochure RAD11063A). 2023 [cited 2024]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12059028/.
  34. Chan WL, Yun HB, Cheung EE, Liu M, Hou LY, Lam KO, et al. Association of sarcopenia with severe chemotherapy toxicities and survival in patients with advanced gastric cancer. Oncologist. 2024;29(10):e1272–9. · DOI
  35. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–6. · DOI · Paper page
  36. Mascarella MA, Ferdus J, Vendra V, Sridharan S, Sultanem K, Tsien C, et al. Sarcopenia predicts short-term treatment‐related toxicity in patients undergoing curative‐intent therapy for head and neck cancer: A systematic review and meta‐analysis. Head Neck. 2024;46(6):1500–9. · DOI
  37. Karavolia E, van Rijn-Dekker MI, Van den Bosch L, van den Hoek JGM, Oldehinkel E, Meijer TWH, et al. Impact of sarcopenia on acute radiation-induced toxicity in head and neck cancer patients. Radiother Oncol. 2022;170:122–8. · DOI
  38. van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, et al. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. N Engl J Med. 2024;391(15):1413–25. · DOI
  39. van As N, Yasar B, Griffin C, Patel J, Tree AC, Ostler P, et al. Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial. Eur Urol. 2024;86(6):566–76. · DOI
  40. Schmidt R, Bajerski D, Bicu AS, Siefert V, Eckl M, Willam M, et al. Feasibility of automated AI-based contouring and stable radiomic feature assessment by HyperSight-CBCT Imaging for adaptive high-precision radiotherapy of prostate cancer. Sci Rep. 2026;16(1). · DOI
  41. Cvachovec P, Bicu AS, Schmidt R, Siefert V, Eckl M, Willam M, et al. Longitudinal stability of HyperSight(TM)-CBCT based radiomic features in patients with CT guided adaptive SBRT for prostate cancer. Sci Rep. 2025;15(1):15863. · DOI

Metadata

Authors
Siefert, V., V. Bettenhausen, J., Bicu, A. S., Schmidt, R., Willam, M., Eckl, M., Stieler, F., Ehmann, M., Buergy, D., Fleckenstein, J., Beuthien-Baumann, B., Schlemmer, H.-P., Froelich, M. F., Schoenberg, S. O., Giordano, F. A., Boda-Heggemann, J., & Dreher, C.
Venue
Radiation Oncology
Published
2026-05-29
Volume
21
Issue
1
ISSN
1748-717X
Cited by
0
References
1
Language
en
Licence
Funders
Medizinische Fakultät Mannheim der Universität Heidelberg

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HyperSightTM-CBCT based monitoring of sarcopenia during definitive radiotherapy of prostate cancer: a longitudinal feasibility study. https://app.cochat.ai/papers/10.1186/s13014-026-02856-3
The paper
Siefert, V., V. Bettenhausen, J., Bicu, A. S., Schmidt, R., Willam, M., Eckl, M., Stieler, F., Ehmann, M., Buergy, D., Fleckenstein, J., Beuthien-Baumann, B., Schlemmer, H.-P., Froelich, M. F., Schoenberg, S. O., Giordano, F. A., Boda-Heggemann, J., & Dreher, C. (2026). HyperSightTM-CBCT based monitoring of sarcopenia during definitive radiotherapy of prostate cancer: a longitudinal feasibility study. Radiation Oncology. https://doi.org/10.1186/s13014-026-02856-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.